linjc16/ctgov huggingface dataset:
A Study of Duloxetine in the Treatment of Fibromyalgia

Study Overview
=================
Brief Summary
-----------------
This study is designed to evaluate duloxetine for the treatment of fibromyalgia syndrome patients.

Official Title
-----------------
A 1-Year Safety Study of Duloxetine in Patients With Fibromyalgia Syndrome

Conditions
-----------------
Fibromyalgia

Intervention / Treatment
-----------------
* Drug: duloxetine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meet criteria for primary fibromyalgia syndrome as defined by the American College of Rheumatologists Exclusion Criteria: Treatment with a monoamine oxidase inhibitor within 14 days prior to Visit 2 or the potential need to take within 5 days after discontinuation from the study. Any patients judged by their physicians to be at serious suicidal risk. Have uncontrolled narrow-angle glaucoma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: duloxetine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate safety and efficacy of duloxetine in patients diagnosed with fibromyalgia syndrome |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate persistence of efficacy |  |  | 
| Evaluate long-term differences in efficacy in different doses |  |  | 
| Evaluate gains in efficacy in non-responders |  |  |
Burdock and Blood Pressure in African-American Women

Study Overview
=================
Brief Summary
-----------------
This is a study of women aged 18-65, to determine the physiological effects of consuming burdock root in supplement form. Burdock has long been used by herbalists for its diuretic and blood sugar lowering properties.

Detailed Description
-----------------
This study will allow us to determine the effect of burdock consumption on basic laboratory tests such as the complete metabolic panel (CMP) as well as the effect on blood pressure over time. Participants will self-monitor their blood pressures and undergo lab testing. They will also complete symptom inventories to determine subjective factors that change with burdock consumption, such as menstrual water retention. Subjects will undergo electronic body composition testing before and after the intervention.

Official Title
-----------------
Burdock and Blood Pressure in African-American Women: A Randomized Controlled Trial

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Dietary Supplement: Burdock
* Dietary Supplement: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be able to swallow tablets African-American race Able to travel to our clinic in Santa Monica Exclusion Criteria: Severely low blood pressure Hypoglycemia Baseline creatinine over 1.2

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Patients will consume a placebo pill containing methylcellulose. | Dietary Supplement: Placebo<br>* Methylcellulose (inert) tablet taken as placebo<br>|
| Active Comparator: Active<br>Patients will consume 850 mg of burdock twice per day. | Dietary Supplement: Burdock<br>* Subjects will consume burdock daily and will undergo laboratory tests to determine the effect of burdock, if any, on organ function.<br>* Other names: Arctium lappa;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure |  | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body fat percentage |  | 6 Weeks | 
| Extracellular/Total Body Water Ratio |  | 6 Weeks | 
| Hemoglobin A1c |  | 6 weeks | 
| Blood urea nitrogen |  | 6 weeks | 
| Creatinine |  | 6 weeks | 
| Fasting Blood Glucose |  | 6 weeks | 
| Liver function tests |  | 6 weeks |
Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases

Study Overview
=================
Brief Summary
-----------------
Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases

Detailed Description
-----------------
Prospective Data Collection of Newly Diagnosed HD and NHL.

Official Title
-----------------
Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases

Conditions
-----------------
Hodgkin Disease, Lymphoma, Non-Hodgkin

Intervention / Treatment
-----------------
* Other: Database


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with newly diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Exclusion Criteria: Patients with diagnosis other than HD and NHL.

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Database|Database|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HD, NHL
Exploring Deployment Stress and Reintegration in Army National Guard Chaplains

Study Overview
=================
Brief Summary
-----------------
The purpose of this 2-year pilot study is to explore the impact of deployment on the psychosocial and health characteristics and reintegration of Military Chaplains, specifically those of the Army National Guard (ARNG). This pilot will serve as the foundation for subsequent investigations of chaplains from multiple branches of the military. In addition to spiritual and religious support, Military Chaplains play a key role in the behavioral health of deployed service-members, routinely participating in suicide prevention training, conducting critical event debriefing, and identifying service-members at risk for combat and operational stress reactions1. A high risk group for exposure to trauma2, Military Chaplains have suffered brain injuries, gunshot wounds and blast injuries in OEF/OIF Theater3. In addition, many report combat related stress issues such as compassion fatigue, PTSD, and reintegration issues3. While the traumatic experiences of OEF/OIF deployed troops have been well documented, the effects on military chaplains caring for these service-members have received little attention in the research to date. We are collaborating with the National Guard Chaplain Corps Leadership on this program of research. The aims of this 2-year pilot cross-sectional study focus on describing and exploring deployment and its impact on psychosocial, health characteristics and reintegration of ARNG chaplains using a mixed method approach (web-based survey, in-depth interviews, social network analysis).

Official Title
-----------------
Exploring Deployment Stress and Reintegration in Army National Guard Chaplains

Conditions
-----------------
Combat Stress Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: current, active members of ARNG during timeframe of OIF/OEF/OND Chaplains able to be contacted by email for survey explanation and participation consent to participate in interview or network questionnaire Exclusion Criteria: not current, active members of ARNG during timeframe of OIF/OEF/OND not Chaplains not able to be contacted by email for survey explanation and participation do not consent to participate in interview or network questionnaire

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>ARNG Chaplains | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| observational |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
war, religion, caregiver, combat stress disorder
Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients

Study Overview
=================
Brief Summary
-----------------
The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of tamoxifen. The investigators want to evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450 subfamilies(CYP2D6, CYP3A4/5 and CYP2C19) in breast cancer patients, and analyze the association between the genetic polymorphisms of cytochrome P450 subfamilies and clinical outcomes in breast cancer patients treated by adjuvant tamoxifen therapy.

Official Title
-----------------
Association Between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients With Tamoxifen Treatment

Conditions
-----------------
Breast Neoplasms, Survival Analysis, Antineoplastic Agents, Therapeutic Uses

Intervention / Treatment
-----------------
* Drug: tamoxifen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age ≥ 18 years Breast cancer patients who underwent surgery Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Breast cancer patients<br>Breast cancer patients who underwent surgery with or without chemotherapy, endocrine therapy and/or radiation therapy. The patients are categorized according to the genetic polymorphisms or the activity score of the cytochrome P450 metabolism. | Drug: tamoxifen<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The frequency of the genetic polymorphisms of CYP2D6 in breast cancer patients |  |  | 
| The frequency of the genetic polymorphisms of CYP3A4/5 in breast cancer patients |  |  | 
| The frequency of the genetic polymorphisms of CYP2C19 in breast cancer patients |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The association between the genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen therapy |  |  | 
| The association between the genetic polymorphisms of CYP3A4/5 and outcomes in breast cancer patients with tamoxifen therapy |  |  | 
| The association between the genetic polymorphisms of CYP2C19 and outcomes in breast cancer patients with tamoxifen therapy |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tamoxifen, Cytochrome P-450 CYP2D6, Polymorphism, Single nucleotide, Antineoplastic Agents, Hormonal
The Efficacy of 308nm Excimer Laser in White Striae

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether 308nm Excimer Laser therapy are effective in the color correction of white striae.

Detailed Description
-----------------
The use of excimer laser in modified program in white striae during a few months.

Official Title
-----------------
The Efficacy of 308nm Excimer Laser in White Striae

Conditions
-----------------
White Striae, Excimer Laser

Intervention / Treatment
-----------------
* Device: Excimer Laser Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: White Striae Exclusion Criteria: Red Striae

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Excimer Laser Therapy|excimer laser is a UV 308nm laser. repeated sessions (10 sessions) needed. once per week.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical darkening of striaes |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Colorimetric assessment |  |  |
Prospective Cohort Study of Intravenous Lipid Emulsion for Resuscitating Critically-ill Poisoned Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this project is to evaluate the case characteristics of patients who receive intravenous lipid emulsion therapy. Previous literature to date has focused on animal studies or has been primarily limited to case reports or small case series. This prospectively collected data set will permit a much more detailed description of the use of lipid, its potential benefits, and potential harms.

Detailed Description
-----------------
The purpose of this project is to evaluate the case characteristics of patients who receive intravenous lipid emulsion therapy. A secondary objective is to determine the mortality in this critically ill population of individuals. Previous literature to date has focused on animal studies or has been primarily limited to case reports or small case series. This prospectively collected data set will permit a much more detailed description of the use of lipid, its potential benefits, and potential harms.

Official Title
-----------------
Prospective Cohort Study of Intravenous Lipid Emulsion for Resuscitating Critically-ill Poisoned Patients

Conditions
-----------------
Overdose

Intervention / Treatment
-----------------
* Other: administration of intravenous lipid emulsion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: receiving intravenous lipid emulsion for treatment of a drug toxicity Evaluation of a medical toxicologist as part of the ToxIC registry consortium Exclusion Criteria: not evaluated by a medical toxicologist participating in ToxIC
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: administration of intravenous lipid emulsion|all patients receive intravenous lipid emulsion at the discretion of the treating provider. This registry prospectively collects detailed information on such patients|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival | The primary objective is to compare survival based on lipophilicity (as measured by LogD) of the drugs | Survival is measured at hospital discharge. The study is open to enrollment indefinitely. It is estimated approximately 100 subjects will be enrolled in 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lipid, ILE, overdose, resuscitation
HUSH Restriction in HIV Infected Patients

Study Overview
=================
Brief Summary
-----------------
HIV eradication faces a major obstacle that is viral persistence in latent reservoir cells despite antiretroviral therapy. Epigenetic repression plays a central role in viral transgene latency and several epigenetic regulators have been involved in this process. Among them, the Human Silencing Hub or HUSH complex, composed of Tasor, MPP8 and periphilin, has been shown to recruit the H3K9me3 methyltransferase SET domain bifurcated 1 (SETDB1) and is therefore responsible for genes' epigenetic repression. Our recent results highlight the ability of Vpx from HIV-2/SIVsmm to counteract HUSH and to reactivate latent viruses in a latency model. We propose here to study HUSH activity along pathogenesis.

Official Title
-----------------
HUSH Restriction in HIV Infected Patients

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Other: Blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for group 1: Symptomatic or asymptomatic acute HIV1 infection Age above 15 years old No ARV treatment prior inclusion (excepted as prophylaxis pre or post exposure) Inclusion Criteria for group 2: Chronic HIV1 infection Age above 18 years old No ARV treatment since at least 3 month (regardless the reason) Inclusion Criteria for group 3: HIV2 Infection Age above 18 years old No ARV treatment since at least 3 month (regardless the reason) Exclusion Criteria for all groups: HIV1 and HIV2 co-infection Evolutive intercurrent pathology, in particular active co-infection (i.e. HBV, HCV, tuberculosis, HTLV1) Life-threatening pathology

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| acute HIV1 infection<br>Patient infected by HIV1, prior treatment initiation | Other: Blood sampling<br>* Peripheral blood sampling on EDTA<br>|
| chronic HIV1 infection<br>Patient infected by HIV1, untreated or without treatment since at least 3 months | Other: Blood sampling<br>* Peripheral blood sampling on EDTA<br>|
| HIV2 infection<br>Patient infected by HIV2, untreated or without treatment since at least 3 months | Other: Blood sampling<br>* Peripheral blood sampling on EDTA<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Viremia | Intracellular HIV RNA load expressed in number of copies / ml | Baseline | 
| Total HIV DNA and integrated HIV DNA | Quantification by qPCR | Baseline | 
| Hush activity | Transcription rate of cellular genes targeted by HUSH by qRT-PCR | Baseline |
The Use of Novel us Device (Jetguide) to Measure the Distance to the Roof of the IAC (Inferior Alveolar Canal)

Study Overview
=================
Brief Summary
-----------------
The purpose of this human clinical trial is to validate the accuracy of Jetguide® US device in detecting the inferior alveolar canal (IAC) and to compare it to measurements performed on computerized tomography images.

Detailed Description
-----------------
To date, the most accurate method to assess the distance from the alveolar crest to the IAC is cone beam computerized tomography (CBCT). This technique carries with it some potential concerns, including measurements errors, inability to perform intra-operative radiographs substantial financial and radiation costs. In the present study patients will have a CBCT of the mandible taken. Sites where implants will be inserted will be marked on the CBCT, measurements of the distance from bone crest to the roof of the inferior alveolar canal (BC-IAC) will be performed. During implant surgery the depth of the osteotomy (OD) will be measured using a periodontal probe; OD and the distance from the bottom of the osteotomy to the roof of the IAC (residual distance - RD) will be measured using a standard JetGuide® device. In addition, standard panoramic radiographs will be taken with a surgical gauge in the osteotomy which will enable us to measure the RD radiographically. The correlation between the radiographic and clinical BC-IAC distance will be the primary outcome variable. The same correlation for the RD between the Jetguide readings and the linear measurements on the panoramic radiographs will serve as the secondary outcome variable.

Official Title
-----------------
The Use of Novel us Device (Jetguide) to Measure the Distance to the Roof of the IAC (Inferior Alveolar Canal)

Conditions
-----------------
Comparison Between Ultrasound and Clinical Measurements

Intervention / Treatment
-----------------
* Device: US depth measurements


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: missing teeth in the premolar and molar areas of the lower jaw Exclusion Criteria: pregnancy pacemakers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Implant osteotomy measurements<br>Drilled implant locations | Device: US depth measurements<br>* Measurement of the distance between the apex of the drilled implant site and the IAC<br>* Other names: Ultrasonic measurement device;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
alveolar nerve, inferior, ultrasound, digital radiography, dental, nerve injury